60 DEGREES PHARMACEUTICALS Business Summary

60 Degrees Pharmaceuticals, Inc. (SXTP) is a specialty pharmaceutical company that generates revenue through the commercialization of therapeutics for infectious diseases, primarily focusing on its FDA-approved antimalarial drug, ARAKODA (tafenoquine). The company operates through two primary business segments: commercial sales of travel medicines and a clinical-stage pipeline targeting vector-borne, fungal, and viral diseases. Its revenue model is driven by product sales via national distributors, supplemented by strategic partnerships with platforms like GoodRx and telehealth providers such as Runway Health to expand patient access. Within the competitive landscape, SXTP contends with microcap biotech firms like Lexaria Bioscience (LEXX), Pasithea Therapeutics (KTTA), and Citius Pharmaceuticals (CTXR); however, it distinguishes itself as a revenue-generating entity with an approved asset currently being repositioned for the underserved babesiosis market, where no FDA-approved treatments currently exist. The company was co-founded in 2010 by Dr. Geoffrey S. Dow, who serves as President and CEO, bringing over 20 years of expertise in tropical disease product development and a 13-year tenure at the Walter Reed Army Institute of Research. The executive leadership team includes Chief Medical Officer Dr. Bryan Smith, a retired military colonel with 30 years of experience in clinical pharmacology, and Chief Commercial Officer Kristen Landon, who has over 26 years of experience in pharmaceutical brand launches. The board of directors features notable industry veterans such as Charles Allen, CEO of BTCS Inc., and Cheryl Xu, Vice President of Public Policy at Biogen. Institutional backing includes DRW Securities, LLC, reflecting the company's strategic focus on capital-efficient clinical advancement and the commercial scaling of its infectious disease portfolio.